Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The Food and Drug Administration (FDA) has approved a Risk Evaluation and Mitigation Strategy plan for the malaria drug Qualaquin (quinine sulfate) to warn against unapproved uses. The plan warns health care professionals and consumers not to use Qualaquin to treat night time leg cramps or restless leg syndrome, because such use has resulted in serious side effects and even death. Qualaquin is approved by the FDA to treat uncomplicated malaria caused by the parasite Plasmodium falciparum, which can be life-threatening if untreated. The drug is sometimes prescribed for restless leg syndrome though that use is not approved by the FDA.

Read the rest of this entry »

The Food and Drug Administration (FDA) has issued a warning to health care professionals to use extreme caution when prescribing Qualaquin (Quinine Sulfate), according to the Postmarket Reviews section of the Volume 2, Number 2 2, 2009 issue of its quarterly online newsletter, Drug Safety News (DSN).

Read the rest of this entry »